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How do we treat life-threatening anemia in a
Jehovah’s Witness patient?
Joseph A. Posluszny Jr and Lena M. Napolitano
The refusal of allogeneic human blood and blood prod-
ucts by Jehovah’s Witness (JW) patients complicates
the treatment of life-threatening anemia. For JW
patients, when hemoglobin (Hb) levels decrease
beyond traditional transfusion thresholds (<7 g/dL),
alternative methods to allogeneic blood transfusion can
be utilized to augment erythropoiesis and restore
endogenous Hb levels. The use of erythropoietin-
stimulating agents and intravenous iron has been
shown to restore red blood cell and Hb levels in JW
patients, although these effects may be significantly
delayed. When JW patients have evidence of life-
threatening anemia (Hb <5 g/dL), oxygen-carrying
capacity can be supplemented with the administration
of Hb-based oxygen carriers (HBOCs). Although
HBOCs are not Food and Drug Administration (FDA)
approved, they may be obtained and administered with
FDA, institutional review board, and patient approval.
We describe a protocol-based algorithm to the manage-
ment of life-threatening anemia in JW patients and
review time to anemia reversal and patient outcomes
using this approach.
T
he management of Jehovah’s Witness (JW)
patients with anemia and bleeding presents a
clinical dilemma as they do not accept alloge-
neic human blood or blood product transfu-
sions.1,2 With increased understanding of the JW patient
beliefs and blood product limitations, the medical com-
munity can better prepare for optimal treatment of severe
life-threatening anemia in JW patients.
Lower hemoglobin (Hb) is associated with increased
mortality risk in JW patients. In a study of 300 patients
who refused blood transfusion, for every 1 g/dL decrease
in Hb below 8 g/dL, the odds of death increased 2.5-fold
(Fig. 1).3 A more recent single-center update of JW
patients (n = 293) who declined blood transfusion
reported an overall mortality rate of 8.2%, with a twofold
increased risk of death per each 1 g/dL decrease in nadir
Hb (unadjusted odds ratio [OR], 1.04; 95% confidence
interval [CI], 1.52-2.74; adjusted OR, 1.82; 95% CI, 1.27-
2.59; Fig. 1).4
A variety of treatment strategies have been used
to improve the efficiency and production of red blood
cells (RBC) and to limit blood loss in JW patients, inclu-
ding erythropoiesis-stimulating agents (ESAs), iron
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supplementation, Hb-based oxygen carriers (HBOCs),
and blood conservation strategies.5 The ultimate goal is to
preserve oxygen-carrying capacity in all ways possible
without allogeneic human blood transfusion. We devel-
oped a standardized treatment algorithm (Fig. 2) for man-
agement of severe anemia in JW patients, using all
available treatments for severe life-threatening anemia.
DEFINITION OF SEVERE ANEMIA
AND MORTALITY RISK
There is no universally accepted definition of severe
anemia. Based on the current literature, which includes
case reports, case series, and retrospective analyses, we
define severe anemia as Hb of less than 5 or 5 to 7 g/dL
with symptoms of hypoperfusion including lactic acido-
sis, base deficit, shock, hemodynamic instability, or coro-
nary ischemia. Retrospective studies have confirmed that
mortality rates significantly increase with Hb concentra-
tions between 5 and 6 g/dL in patients who refuse alloge-
neic transfusion.6 We initiate our anemia protocol in all JW
patients with a Hb level of less than 7 g/dL, but we con-
sider the use of HBOCs in patients with a Hb level of less
than 5 to 6 g/dL with examination of the individual
patient’s anemia tolerance and adequacy of oxygen deliv-
ery including assessment of adequacy of perfusion,
cardiac complications, and lactate or base deficit.
In JW patients, two additional
studies have shown that other patient
factors in addition to anemia are risk
factors for mortality. The additional
risk factors identified by the Auckland
Anemia Mortality Risk Score (Auckland
AMRS) include age of at least 45 years of
age, weight of at least 90 kg, hyperten-
sion, cardiac arrhythmia, angina, previ-
ous myocardial infarction (MI), valvular
heart disease, heart failure, being on
hemodialysis, acute admission, and Hb
level of not more than 8 g/dL on admis-
sion to the hospital. A composite score
of these risk factors stratifies mortality
rates of 4% to 83% (AMRS 0-3, 4%
mortality; AMRS 4-5, 32% mortality;
AMRS 6-7, 50% mortality; AMRS ≥ 8,
83% mortality).7
The Hamilton AMRS further refined
their risk model by including treatment-
related mortality risk factors during
hospitalization (shock, acute gastro-
intestinal bleeding, pneumonia, nadir
Hb ≤ 7 g/dL, sepsis, worse congestive
heart failure, neurologic complications
[stroke and hypoxic encephalopathy]).
Higher Hamilton AMRS scores were associated with high
mortality (0-2, 4% mortality; 3-4, 29%; 5, 40%; ≥6, 67%).8
Although these risk assessment scores have not yet been
validated in large multicenter studies, they promote the
fact that there are high mortality rates associated with
anemia in JW patients.
TREATMENT STRATEGIES FOR
SEVERE ANEMIA
A multimodal approach is commonly required for treat-
ment of JW patients with severe anemia, including treat-
ments to enhance endogenous erythropoiesis, reduce
blood loss, increase oxygen delivery, reduce oxygen con-
sumption, and avoid hemodilution and iatrogenic anemia.
ESAs
Exogenous ESAs are an effective anemia therapy by
inducing proliferation and terminal differentiation of
endogenous erythroid cells and prevention of erythroid
cell apoptosis in the marrow.9 ESAs also exert a potent
protective effect against hypoxia by induction and activa-
tion of hypoxia inducible factor-1α with antiapoptotic
action.10 ESAs may also affect renal tubular function
leading to a decrease in plasma volume and a relative
increase in Hb levels.11 RBC expansion with ESA therapy is
evidenced by an increase in reticulocyte count by Day 3 of
6 
16 31 
49 58 133 293 
Fig. 1. Mortality rates in patients (n = 293) who decline blood transfusion stratified
by nadir postoperative Hb concentrations in two published studies. The last pair of
bars represent the data from Carson and colleagues3 adjusted according to the
number of EHMC patients in each nadir Hb category. EHMC cohort had no patient
with nadir Hb level of less than 2 g/dL. Numbers at the top reflect “n” in each group.
EHMC = Englewood Hospital and Medical Center. From Shander A, Javidroozi M,
Naqvi S et al. An update on mortality and morbidity in patients with very low post-
operative Hb levels who decline blood transfusion. Transfusion. 2014 Feb 17. [Epub
ahead of print]4 Carson = Carson JL, Noveck H, Berlin JA et al. Mortality and morbid-
ity in patients with very low postoperative Hb levels who decline blood transfusion.
Transfusion 2002;42:812-8.
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treatment in patients who are iron replete, with the
equivalent of 1 blood unit produced by Day 7 of ESA treat-
ment.12 As a result, the effects of ESAs on overall RBC
number or Hb level may not be present for several days
after initial administration. ESA therapy, despite its
delayed effect, is a valuable tool for JW patients for whom
allogeneic blood transfusion is not an option.
ESAs are not recommended for anemia treatment in
critically ill patients. A meta-analysis of nine RCTs con-
firmed that ESA use in critically ill patients was associated
with a decreased number of transfused patients (OR, 0.73;
95% CI, 0.64-0.84; I2 = 54.7%) and a small reduction in the
mean number of units (0.41 unit) transfused per patient
(95% CI, 0.10-0.74; I2 = 79.2%)13 and another study docu-
mented potential increase in venous thromboembolism.14
However, in the severely anemic JW patient, any increase in
erythropoiesis via ESAs may be life-
saving. It has, however, been docu-
mented that high pharmacologic ESA
doses can overcome the erythropoietin
(EPO) resistance seen in the anemia of
inflammation which is common
in critically ill15 and severe anemia
patients.16
The optimal ESA dose for treatment
of JW patients with severe anemia is
unknown. A randomized trial of six dif-
ferent ESA dosing regimens in critically
ill patients determined that all were well
tolerated and appeared to effect reticu-
locytosis with a peak on Day 11 or Day
15. Interestingly, the pharmacokinetics
did not predict the pharmacodyna-
mics response in anemic critically ill
patients.17 Our protocol uses 40,000
units of EPO IV of subcutaneous daily
until the Hb level is more than 7 g/dL.
Furthermore, adequacy of iron supple-
mentation was in question in this
study.18 This is an important issue, as
maximal erythropoietic response will
not be achieved with ESAs if relative iron
deficiency occurs. Iron-deficient eryth-
ropoiesis was documented in critically
ill patients treated with ESAs and intra-
venous (IV) iron with confirmation of
elevated zinc protoporphyrin concen-
trations.19 No specific studies have yet
examined the optimal ESA dose in JW
patients with severe anemia.
Iron supplementation
Adequate iron stores are necessary to
ensure adequate erythropoiesis.20
Similar to ESAs, the effect of iron on Hb level is not imme-
diate. The combination of daily ESA and IV iron adminis-
tration has proven to be effective in increasing Hb levels
and preventing transfusion in multiple clinical scenarios
that often require blood transfusion including those with
burn injury,21 gastrointestinal hemorrhage,2 thoracic,
splenic and exsanguinating extremity trauma,22,23 chemo-
therapy,24 and total hip arthroplasty.25
Functional iron deficiency is common in critically ill
and hospitalized patients related to “anemia of inflamma-
tion.”26 Inflammation induces up regulation of hepcidin,
an acute-phase protein made by the liver, which reduces
iron availability by decreased absorption of iron across the
gastrointestinal tract, inhibition of iron efflux through
ferroportin (the sole known iron exporter of enterocytes,
macrophages, and hepatocytes) and decreased release of
 
Ini?ate Anemia Protocol: 
ESA: Epoe?n alfa 40,000 units IV or subcutaneous 
daily un?l Hb > 7 g/dL, then change dosing to
40,000 units weekly
Iron: 100 mg iron sucrose intravenous daily for 10 
days minimum and then consider conversion to 
oral iron supplementa?on 
Vitamin C: 500 mg TID, except in renal failure (qD) 
Folate: 1 mg PO or IV qD 
Vitamin B12: consider IV vs. oral supplementa?on   
• Monitor Hb and methemoglobin daily with
blood gas (0.3 ml)  
• Control any bleeding + correct coagulopathy 
(tranexamic acid, recombinant factor VIIa, 
prothrombin complex concentrate) 
• Op?mize ionized calcium (1.2-1.3) 
• Reduce oxygen consump?on (control fever, 
tachycardia, agita?on, work of breathing, etc.) 
• Supplemental oxygen  to maintain saO2 > 95%  
• Avoid hemodilu?on, diuresis if possible to 
achieve hemoconcentra?on 
JW Pa?ent with Severe Anemia 
Hb < 7 g/dL
Evaluate for Cri?cal Anemia 
Check arterial (ABG) or venous (VBG) 
blood gas with lactate and base deficit 
Evaluate for hypoperfusion, shock, 
hemodynamic instability, hemorrhage 
Evaluate for cardiac ischemia 
Hb < 5 g/dL 
Consider HBOC 
treatment 
Hb > 5 g/dL 
No HBOC treatment 
required 
Cri?cal Anemia 
Present? 
YES NO 
HBOC Treatment 
Goal total (cellular & 
free) Hb > 6 g/dL 
 
Hemopure: 1 unit is ~225 
mL administered IV over 4 
hours or less if bleeding;  
if pa?ent develops 
hypertension, slow 
infusion rate  
Fig. 2. Severe anemia protocol for JW patients.
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iron from macrophages and the reticuloendothelial
system.
There is no definitive diagnostic laboratory method
by which iron deficiency can be established in critically ill
JW patients since most diagnostic iron studies are altered
related to the inflammatory response. Iron supplementa-
tion is administered in all JW patients in an effort to
increase endogenous erythropoiesis and maximize effi-
cacy of ESAs. IV iron administration is used, given that
high hepcidin concentrations impair enteral iron absorp-
tion by the gut. Our institutional protocol uses IV iron
sucrose 100 mg daily for 10 days or until the Hb concen-
tration is stable at more than 7 g/dL. Higher daily doses
may be considered in patients with severe life-threatening
anemia.
Treatment of other anemia etiologies
Nutritional deficiencies are additional potential etiologies
of anemia. If previous diagnostic assessment of other
anemia etiologies has not been completed, then assess-
ment for folate and vitamin B12 deficiency is recom-
mended. Empiric folate and B12 supplementation is
administered if diagnostic laboratory testing is not
possible.
HBOCs
HBOC (Table 1) administration is considered in JW
patients with severe life-threatening anemia. Recently,
Hemopure (HBOC-201, purified, cross-linked acellular
bovine Hb in a modified lactated Ringer’s solution, OPK
Biotech, Cambridge, MA) was the only HBOC available for
clinical use requiring patient consent, institutional review
board approval, and Food and Drug Administration (FDA)
emergency investigational new drug (IND) approval for
use in individual patients. At present, it is uncertain
whether Hemopure will continue to be made available for
clinical use in patients in the United States.
Hemopure is approved for human use in South Africa
for the treatment of adult surgical patients who are acutely
anemic and is also approved for use as an oxygen carrier in
Russia. Englewood Hospital has initiated an “Expanded
Access Study of HBOC-201 (Hemopure) for the Treatment
of Life-Threatening Anemia” to provide Hemopure to
patients with life-threatening anemia (Hb < 6 g/dL) when
allogeneic transfusion is not an option (NCT01881503).27
Sanguinate (Prolong Pharmaceuticals, South Plain-
field, NJ) is a bovine PEGylated carboxyHb and was devel-
oped to combine the beneficial functions of a carbon
monoxide-releasing molecule (to promote anti-
inflammatory and antivasoconstriction effects) with an
oxygen transfer agent. A Phase I safety study was recently
completed, and no serious adverse events were reported.28
A Phase Ib trial in sickle cell patients is currently under
way (NCT01374165). Sanguinate is also available for use
under an expanded access emergency IND program for
treatment of JW patients with severe anemia.
Our experience with HBOCs for JW patients is
with Hemopure. Hemopure can bridge between life-
threatening anemia and the time it takes for ESA and/or
iron therapy to restore endogenous Hb levels. Hemopure
does not require ABO screening; is stable at room tem-
perature for 3 years; and does not require refrigeration,
warming, or reconstitution. One unit of Hemopure
includes 32.5 g of polymerized bovine Hb in approxi-
mately 225 to 250 mL of a solution similar to lactated
Ringer’s, increases the plasma Hb level 0.63 g/dL,29 and
has a half-life of approximately 19 hours. Therefore,
Hemopure provides a transient improvement in oxygen
delivery. Hemopure administration is not FDA-approved.
Concerns with HBOC administration include the
vasoactive side effects associated with nitric oxide scav-
enging that may lead to hypertension, coronary artery
vasoconstriction, MI, and increased mortality. This higher
death rate is potentially of great concern. A meta-analysis
reviewed data on death and MI as outcome variables in 16
trials in adult patients (n = 3711) involving five different
TABLE 1. HBOCs status as of 2014
Product class Product Company Technology Status
Cross-linked Hb HemAssist (ααHb,
DClHb)
Baxter Cross-linked Hb Discontinued; safety; increased
mortalityUS Army Cross-linked Hb
rHb 1.1 Somatogen Recombinant Hb Discontinued; safety; hypertension
rHb 2.0 Baxter Recombinant Hb Discontinued; safety
Polymerized Hb PolyHeme Northfield Laboratories Gluteraldehyde, pyridoxal
human Hb
Discontinued; safety
HBOC-201
(Hemopure)
OPK Biotech Gluteraldehyde bovine Hb Discontinued, approved for use
in South Africa and Russia
HemoLink Hemosol Polymerized human Hb Discontinued; safety; MI
Conjugated Hb PHP Apex Bioscience PEG-human Hb Discontinued
PEG-Hb Enzon PEG-bovine Hb Discontinued
Hemospan/MP4 Sangart PEG-human Hb Discontinued; no efficacy
Sanguinate Prolong Pharmaceuticals PEGylated carboxyhemoglobin
bovine
Phase I clinical trials
PEG = polyethylene glycol; PHP = pyridoxylated Hb polyoxyethylene conjugate.
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HBOCs in varied patient populations.30 They reported a
significant increase in the risk of death (164 deaths vs. 123
deaths; relative risk, 1.30; 95% CI, 1.05-1.61) and MI
(59 MIs vs. 16 MIs; relative risk, 2.71; 95% CI, 1.67-4.40).
There are, however, some limitations to this meta-
analysis31: multiple products (HemAssist, PolyHeme,
Hemolink, Hemopure, Hemospan; Table 1) were included
in this analysis, lack of consistent monitoring of cardiac
events in these studies, lack of consistent treatment in the
perioperative period to prevent cardiac events in the sur-
gical studies, no identification of specific cardiac risk in
patients enrolled in these studies, and lack of control for
risk of myocardial events and mortality that may have
been related to allogeneic RBC transfusion.32-34 Hemopure
may also lead to methemoglobinemia, which is a minimal
risk with 1- to 2-unit transfusions and is rarely symptom-
atic unless methemoglobin is more than 10%.
Given the lack of alternatives, time needed for
ESAs and iron to augment erythropoiesis, and the high
mortality of severe anemia in JW patients, Hemopure may
be administered under compassionate-use FDA guide-
lines.35 The FDA requires that we provide a standardized
slideset (provided by the FDA when emergency IND
approved) to review all possible associated risks and com-
plications of HBOCs (including increased mortality and
increased MI rates in prior human clinical trials) with the
JW patient when obtaining informed consent for HBOC
administration.
Under the FDA’s Expanded Access program,
Hemopure has been used to treat severe anemia in JW
patients after induction chemotherapy for leukemia,36
burns,37 trauma,38 and autoimmune hemolytic anemia.39
Hemopure or HBOCs are not a replacement for human
allogeneic blood transfusion, but in cases of life-
threatening anemia in JW patients for which blood trans-
fusion is not an option, it may be life-saving.35,40
Minimizing phlebotomy and diagnostic
blood testing
Prevention of blood loss related to phlebotomy for diag-
nostic laboratory testing is critically important in patients
with severe anemia. In our protocol, phlebotomy is
limited to a maximum of 0.3 to 1 mL daily (using arterial
or venous blood gas syringe) with preference for every
other day laboratory testing if possible. Blood gas testing
provides adequate diagnostic testing to include Hb and
methemoglobin percentage. For other diagnostic testing,
pediatric tubes should be used.
SEVERE ANEMIA PROTOCOL FOR
JW PATIENTS
We established a clinical protocol for the treatment of
severe anemia in JW patients to provide early standard-
ized treatment (Fig. 2).
ESAs and iron treatment
For any JW patient with Hb level of less than 7 g/dL, ESA
(epoetin alfa, Procrit, Amgen, Inc., Thousand Oaks, CA) is
administered daily (40,000 units) until the Hb level is more
than 7 g/dL. ESA dosing is reduced thereafter and long-
term ESA needs are determined on an individual basis.
Iron sucrose 100 mg IV is administered concurrent with
ESA therapy daily until the Hb level is more than 7 g/dL.
Subsequently, oral iron may be substituted if gastrointes-
tinal function is adequate. Venous duplex monitoring is
considered in patients with high risk for venous thrombo-
embolism, as ESA use is associated with increased venous
thromboembolism rates41 in cancer42 and critical illness.14
HBOC indications and administration
HBOC administration is considered in JW patients when
the Hb level is less than 5 or 5 to 7 g/dL with associated
symptoms of hypoperfusion. One unit of Hemopure
should increase the Hb level by 0.63 mg/dL, but the half-
life of 19 hours is short and must be considered in the daily
assessment of the severity of anemia.
Hemopure can be administered via standard IV
tubing and should be infused slowly over 4 hours (60 mL/
hr) to avoid potential vasoconstrictive effects. If hyperten-
sion develops, the infusion should be held until resolution
of the hypertension. Methemoglobin must be monitored,
and any methemoglobin more than 10% and/or develop-
ment of cyanosis or shortness of breath should caution
additional transfusions of Hemopure. Methylene blue can
be considered to reverse methemoglobinemia associated
with cyanosis, altered mental status, or respiratory
depression.
HBOC institutional review board or FDA approval
and informed consent
HBOC use for the treatment of severe life-threatening
anemia in JW patients requires FDA approval by physician
request for an individual-patient emergency IND, and the
manufacturer must agree to provide the HBOC free of
charge.43 Once the decision has been made that HBOC
transfusion is indicated, the following steps are required
to ensure the safe and responsible acquisition of HBOC
(typically, this process takes 24-48 hours, so anticipation
of the need for HBOC is essential):
1. Contact a physician in your institution familiar with
HBOC transfusion;
2. Contact manufacturer (OPK Biotech, Prolong Phar-
maceuticals) to confirm that they are willing to supply
HBOC free of charge;
3. Obtain FDA approval for administration via compas-
sionate use protocol (emergency IND) http://
www.fda.gov/Drugs/DevelopmentApprovalProcess/
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HowDrugsareDevelopedandApproved/Approval
Applications/InvestigationalNewDrugIND
Application/ucm107434.htm;
4. Obtain institutional review board approval;
5. Obtain informed consent from the patient or
representative.
Case series of patients treated with anemia
protocol for JW patients
The following cases highlight the use of HBOC as an
oxygen carrier bridge until ESAs and iron supplementa-
tion help to augment endogenous erythropoiesis. Six JW
patients were treated with this protocol including HBOC
infusion over 2 years (2012-2014; Table 2). Twenty-eight
units of Hemopure were transfused. Figure 3A shows the
progressive, but not immediate, Hb increase with the use
of Hemopure as a temporary bridge until the effects
of ESA and/or iron were evident in nonsurgical patients.
Figure 3B demonstrates time-dependent Hb changes in
patients who require surgery. In these cases, total Hb was
estimated with blood gas Hb measurements rather than
separate cellular Hb (complete blood count) and free
Hb (reflecting HBOC Hb) tests. In Patient 2, this
protocol was used to achieve a Hb level of more than
7 g/dL before total colectomy for an ulcerative colitis
flare with ongoing bleeding. In Patient 3, 2 units of
Hemopure were administered in the operating room
during an above-knee amputation. Hb increased to more
than 7 g/dL typically 6 to 10 days after protocol
initiation.
There were no direct complications associated with
Hemopure administration. One of the 28 transfusions was
associated with hypertension and resolved with slowing of
the transfusion rate. The highest methemoglobin was
9.3%, and no related symptoms were evident. Five
patients had duplex surveillance with only one positive for
an infrapopliteal deep venous thrombosis that was not
treated. Interestingly, two patients with ARMS scores of 6
to 7 (50% predicted mortality) survived, while the patient
with the highest score (8; >83% predicted mortality)
died.
FUTURE THERAPIES FOR ANEMIA IN
JW PATIENTS
Since a number of studies have confirmed that high
hepcidin concentrations contribute to the anemia of
inflammation, newer treatment strategies are now focus-
ing on antihepcidin therapeutics.44,45 Hepcidin levels
increase to extremely high levels in critically ill trauma
patients and are positively correlated with the duration of
anemia.46 Interestingly, it has been shown that a single
dose of ESA can result in rapid suppression of blood
hepcidin concentrations.47
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Ongoing clinical trials are testing the efficacy of
hepcidin antagonists. The hepcidin inhibitor NOX-H94
(a structured mirror-image RNA oligonucleotide,
Spiegelmer) has completed Phase I trials in healthy
humans and is currently in a Phase II trial to treat anemia
associated with chronic disease.48 LY2787106, a humanized
antibody designed to bind and neutralize hepcidin, is
being investigated in a Phase I clinical trial in patients with
cancer-associated anemia (NCT01340976). Anticalin
(therapeutic protein derived from human lipocalins) PRS-
080 specifically binds human hepcidin with subnanomolar
affinity, and clinical trials are scheduled.49,50
Is it time for antihepcidin treatment for JW patients
with severe anemia? We will await the results of these clini-
cal trials to determine the efficacy of hepcidin antagonists
as novel therapeutics for iron-restricted anemias includ-
ing anemia of inflammation (formerly known as “anemia
of chronic disease”) and continue our search for optimal
therapies of anemia in JW patients.
In conclusion, JW patients with severe life-
threatening anemia present a challenging clinical
problem. Methods to augment endogenous erythropoi-
esis and minimize phlebotomy can successfully manage
anemia. In situations of life-threatening critical anemia,
HBOCs can bridge patients until endogenous Hb levels
are adequate with support from pharmacologic treatment
strategies (ESAs, iron, folate, vitamin B12). The use of a
severe anemia protocol for JW patients can serve as a
foundation for management of these challenging patients.
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